GE Healthcare unveiled at RSNA 2009 a software technique that uses low-frequency sound waves in combination with MRI to measure the elasticity of liver tissue as an indicator of disease.
GE Healthcare unveiled at RSNA 2009 a software technique that uses low-frequency sound waves in combination with MRI to measure the elasticity of liver tissue as an indicator of disease. The technology underlying this new product, called MR-Touch, was developed at the Mayo Clinic in Rochester, MN, and licensed to GE. It extends the principles of physical palpation and MR as a way to evaluate tissue stiffness.
GE is framing MR-Touch as a precise, noninvasive and cost-effective way to detect, monitor, and understand disease. The FDA-cleared technique detects changes in the liver that indicate the presence of disease. It can also be used to monitor disease progression and provide more informed preventive guidance. Perhaps most important, the method supports a comfortable experience for the patient.
MR-Touch will be commercially available as an option to GE's newly released wide-bore 1.5T MR scanner, the Optima MR450w.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.